639 related articles for article (PubMed ID: 30079432)
1. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
3. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
Huhn AS; Finan PH; Gamaldo CE; Hammond AS; Umbricht A; Bergeria CL; Strain EC; Dunn KE
Sci Transl Med; 2022 Jun; 14(650):eabn8238. PubMed ID: 35731889
[TBL] [Abstract][Full Text] [Related]
4. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
6. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
[TBL] [Abstract][Full Text] [Related]
7. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
8. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.
Tompkins DA; Smith MT; Mintzer MZ; Campbell CM; Strain EC
J Pharmacol Exp Ther; 2014 Feb; 348(2):217-26. PubMed ID: 24227768
[TBL] [Abstract][Full Text] [Related]
9. Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC
Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907
[TBL] [Abstract][Full Text] [Related]
10. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.
Dunn KE; Weerts EM; Huhn AS; Schroeder JR; Tompkins DA; Bigelow GE; Strain EC
Addict Biol; 2020 Jan; 25(1):e12680. PubMed ID: 30295400
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
Ahmadi J; Jahromi MS; Ehsaei Z
Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.
Bergeria CL; Tan H; Antoine D; Weerts EM; Huhn AS; Hobelmann JG; Dunn KE
Exp Clin Psychopharmacol; 2023 Feb; 31(1):194-203. PubMed ID: 35266779
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal.
Srivastava A; Kahan M; Njoroge I; Sommer LZ
Can Fam Physician; 2019 May; 65(5):e214-e220. PubMed ID: 31088887
[TBL] [Abstract][Full Text] [Related]
15. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
Sanders NC; Mancino MJ; Gentry WB; Guise JB; Bickel WK; Thostenson J; Oliveto AH
Exp Clin Psychopharmacol; 2013 Aug; 21(4):294-302. PubMed ID: 23855333
[TBL] [Abstract][Full Text] [Related]
16. Naltrexone shortened opioid detoxification with buprenorphine.
Umbricht A; Montoya ID; Hoover DR; Demuth KL; Chiang CT; Preston KL
Drug Alcohol Depend; 1999 Oct; 56(3):181-90. PubMed ID: 10529020
[TBL] [Abstract][Full Text] [Related]
17. Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome.
Dunn K; Bergeria C; Huhn AS; Strain EC
Drug Alcohol Depend; 2020 Oct; 215():108212. PubMed ID: 32781310
[TBL] [Abstract][Full Text] [Related]
18. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
